MSB said they are currently in talks with a potential CHF partner and both parties are looking at biomarkers currently. Who are MSB also in talks with at the moment? Novartis. I think there's a chance Novartis want in on CHF too given the potential for complimentary treatment with entresto.
I have been saying this for ages @Davidboon but the naysayers just laugh at the suggestion …. The synergies of Rexlemestrocel-L with Entresto seem extraordinary given the results we have seen ….
….. you would also anticipate that whoever was looking to partner CHF would want a seat at the table at the FDA meeting coming up next quarter so they will most likely need to finalise this deal prior to the meeting - just sayin’
Tick tock as they say !
MSB Price at posting:
$2.19 Sentiment: Hold Disclosure: Held
…. The synergies of Rexlemestrocel-L with Entresto seem extraordinary given the results we have seen ….
(20min delay)